D-0400-2026 Class II Ongoing
FDA drug recall D-0400-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Mar 9, 2026 and is designated Class II. Reason for recall: Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient. The recall status is ongoing. Affected quantity: 60,541 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 18, 2026
- Initiation Date
- Mar 9, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 60,541 bottles
Product description
Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1592-7
Reason for recall
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Distribution pattern
Nationwide in the USA
Code information
Lot #: S2520249, S2520250, S2520267, Exp. Date 2027/Jan; S2520303, S2520305, S2520332, Exp. Date 2027/Feb; S2540208, S2540209, Exp. Date 2027/Apr
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0400-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026